Sign in to fuzzto save your conversations, follow your research and come back anytime.
Jeena Sikho Lifecare
JSLL
NSE
BSE
NSEBSESectorHealthcare
501.45
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Jeena Sikho Lifecare shows steady capacity expansion and strong profitability, though EBITDA margins face mild pressure and foreign investors have reduced stakes.
Gross Profit climbed from ₹15,593 to ₹19,873 from Q1 FY26 to Q1 FY27, demonstrating consistent top-line conversion.
EBITDA Margin fluctuated between 45% in Q1 FY26 and 48% in Q2 FY26, then settled at 41% in Q1 FY27, reflecting manageable cost pressures.
Operational bed capacity expanded from 2,179 to 2,400 from Q1 FY26 to Q1 FY27, confirming successful infrastructure rollout.
FII Shareholding ranged from 6.17% in Q1 FY26 to 6.63% in Q4 FY26, then dropped to 5.14% in Q1 FY27, signaling foreign investor profit booking.
Video-Call Consultations grew from 41,789 to 69,119 from Q1 FY26 to Q1 FY27, highlighting robust telemedicine adoption.
Operating Expenses rose from ₹7,714 to ₹11,266 from Q1 FY26 to Q4 FY26, then eased to ₹10,662 in Q1 FY27, reflecting controlled cost scaling.
Healthcare Personnel surged from 711 to 959 from Q2 FY26 to Q1 FY27, supporting expanded service delivery.
Franchisee Centres held at 35 in Q2 FY26, stayed 35 in Q3 FY26, then declined to 31 in Q1 FY27, suggesting a strategic shift toward owned facilities.
Profit After Taxes rose from ₹5,131 to ₹6,569 from Q1 FY26 to Q1 FY27, showing resilient net earnings.
Depreciation & Amortisation increased from ₹965 to ₹1,121 from Q1 FY26 to Q3 FY26, then moderated to ₹1,533 in Q1 FY27, aligning with asset growth.